Novo Nordisk to Launch Cheaper Ozempic Copy in South Africa Through Acino Partnership
Key Insights
Novo Nordisk is partnering with Acino (search) to release a lower-cost version of its diabetes drug Ozempic in South Africa, set to debut on July 27.
The launch will make this the only authorized semaglutide copy available in the region, according to official statements.
The initiative aims to increase patient access to essential diabetes treatment in the South African market.
Danish pharmaceutical giant Novo Nordisk is set to launch a more affordable version of its blockbuster diabetes drug Ozempic in South Africa, marking a significant step toward expanding access to essential GLP-1 receptor agonist therapy in the region. The drug is scheduled to debut on July 27, according to official statements.
The initiative comes through a partnership with Acino (search), a pharmaceutical company that will collaborate with Novo Nordisk to bring the lower-cost semaglutide product to market. Once launched, this will become the only authorized semaglutide copy available in South Africa, positioning Novo Nordisk to address significant unmet needs in diabetes care across the region.
The move reflects a growing trend among multinational pharmaceutical companies to implement tiered pricing strategies and authorized generic-like arrangements in low- and middle-income countries, where the burden of type 2 diabetes (search) continues to rise and access to innovative therapies remains constrained by cost.
Semaglutide, the active ingredient in Ozempic, is a glucagon-like peptide-1 (GLP-1) receptor agonist that has demonstrated significant efficacy in glycemic control and cardiovascular risk reduction. By offering a cheaper version through the Acino (search) partnership, Novo Nordisk aims to broaden patient reach while maintaining product quality and supply chain integrity.
Further details regarding the specific pricing structure, manufacturing arrangements, and distribution plans were not disclosed in the official announcement. The launch represents a notable development in the global effort to improve equitable access to diabetes pharmacotherapy.